BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
34.72
-0.13 (-0.37%)
May 9, 2025, 11:26 AM - Market open
BridgeBio Pharma Employees
As of December 31, 2024, BridgeBio Pharma had 730 total employees, including 725 full-time and 5 part-time employees. The number of employees increased by 174 or 31.29% compared to the previous year.
Employees
730
Change (1Y)
174
Growth (1Y)
31.29%
Revenue / Employee
$174,541
Profits / Employee
-$915,025
Market Cap
6.59B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
BBIO News
- 2 days ago - BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 - GlobeNewsWire
- 9 days ago - BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - BridgeBio Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 11 days ago - BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM - GlobeNewsWire
- 17 days ago - BridgeBio: Early Signs Point To Blockbuster Revenues - Seeking Alpha
- 17 days ago - BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET - GlobeNewsWire
- 27 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM - GlobeNewsWire